Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Tristel ( (GB:TSTL) ).
Tristel plc announced that its CEO, Matthew Sassone, has purchased 3,500 ordinary shares of the company at 310 pence per share, increasing his beneficial interest to 0.007% of the total issued share capital. This move may signal confidence in the company’s future prospects and could positively influence stakeholder perceptions, reinforcing the company’s market position in the infection prevention industry.
More about Tristel
Tristel plc is a global infection prevention company specializing in the manufacture and supply of products utilizing its proprietary chlorine dioxide chemistry. The company is a leader in manual decontamination of medical devices, supplying hospitals with products under the Tristel brand, and offers sustainable sporicidal surface disinfection solutions under the Cache brand. Tristel operates globally from its headquarters in Snailwell, near Cambridge, with approximately 250 employees across 14 subsidiaries, selling into 40 countries. It has been listed on the London Stock Exchange’s AIM market since 2005.
YTD Price Performance: -25.84%
Average Trading Volume: 70,408
Technical Sentiment Signal: Buy
Current Market Cap: £147.9M
Learn more about TSTL stock on TipRanks’ Stock Analysis page.